CES 2026 just kicked off, and already Withings is making waves with its Body Scan 2. Sources tell Automatica Press the French health tech company is positioning this not just as a smart scale, but as a 'longevity station'—a one-stop shop for predicting health risks before they become full-blown crises.
Beyond Weight: A Biomarker Bonanza
Forget just tracking pounds; the Body Scan 2 monitors over 60 longitudinal biomarker measurements. We're talking Impedance Cardiography (ICG) to check heart pumping efficiency, Bioimpedance Spectroscopy (BIS) for cellular health analysis, and even hypertension risk notifications. Apparently, Withings is side-stepping blood tests by analyzing foot sweat and cellular membranes. Bold move.
This isn't your average scale; it's trying to be your personal early warning system. MacRumors reports that the Body Scan 2 generates a 'Health Trajectory' score, predicting your healthy lifespan based on the biomarker data. It also tracks heart age, potential prediabetes indicators, and artery elasticity. Customizable tracking and automatic scans? Color me intrigued.
Design Tweaks and Data Privacy
Big change: the color display has moved from the base to the retractable handle, which now houses four electrodes. Combined with the eight EKG-capable electrodes on the glass surface, Withings claims this creates a full-body circuit for more accurate measurements. It's all about that data, folks.
Withings is clearly aware of privacy concerns, stating that the device complies with GDPR and HIPAA standards. All health data is encrypted, which is non-negotiable in today's climate. But can users really trust a tech company with such intimate details? That's the million-dollar question.
The Price of Longevity
The Body Scan 2 is slated to launch in Q2 2026 for $600, pending FDA clearance for its hypertension and atrial fibrillation detection features. A launch is also planned in the U.K., Australia, and Europe. The original Body Scan will still be available for $399.
$600 is a steep price, even for the health-conscious. But if Withings delivers on its promise of early disease detection and longevity prediction, it could be a game-changer. The question is, will consumers trust a smart scale to tell them how long they'll live? And more importantly, will they like what it has to say?